Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

• Status: Completed
• Trial end date: 2017-11-16
• Target enrollment: 0
• Participant gender: All

Summary

A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: BMS-986165

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Male and female, ages 18 to 70 years

• Diagnosis of plaque psoriasis for 6 months

• Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test, must not be pregnant, lactating, breastfeeding or planning pregnancy

• Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment plus 5 half-lives of the study drug plus 90 days.

Exclusion Criteria:

• Any significant acute or chronic medical illness

• Blood transfusion within 4 weeks of study drug administration

• Inability to tolerate oral medication

• Positive hepatitis-B (HBV) surface antigen

• Positive hepatitis-C (HCV) antibody

• Any history or risk for tuberculosis (TB)

• Any major illness/condition or evidence of an unstable clinical condition

• Chest X-ray findings suspicious of infection at screening

• has received ustekinumab, secukinumab or ixekizumab within 6 months of first administration of study medication

• Has received anti-Tumor Necrosis Factor (TNF) inhibitor(s) within 2 months of first administration of study medication

• Has received Rituximab within 6 months of first administration of study medication

• Topical medications/treatments for psoriasis within 2 weeks of the first administration of any study medication

• Any systemic medications/treatments for psoriasis within 4 weeks of the first administration of any study medication

Other protocol defined inclusion/exclusion criteria could apply